A detailed history of First National Bank Of Omaha transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, First National Bank Of Omaha holds 10,414 shares of SUPN stock, worth $379,069. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,414
Previous 12,115 14.04%
Holding current value
$379,069
Previous $413,000 32.69%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$25.99 - $33.85 $44,208 - $57,578
-1,701 Reduced 14.04%
10,414 $278,000
Q1 2024

May 10, 2024

SELL
$27.11 - $35.17 $14,910 - $19,343
-550 Reduced 4.34%
12,115 $413,000
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $34,466 - $45,024
-1,517 Reduced 10.7%
12,665 $366,000
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $7,278 - $8,688
-264 Reduced 1.83%
14,182 $390,000
Q1 2023

May 03, 2023

SELL
$34.93 - $42.03 $20,259 - $24,377
-580 Reduced 3.86%
14,446 $523,000
Q4 2022

Feb 08, 2023

SELL
$31.09 - $37.88 $42,593 - $51,895
-1,370 Reduced 8.36%
15,026 $536,000
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $18,339 - $22,556
-637 Reduced 3.74%
16,396 $555,000
Q2 2022

Sep 06, 2022

BUY
$25.33 - $34.25 $16,768 - $22,673
662 Added 4.04%
17,033 $493,000
Q1 2022

May 25, 2022

SELL
$28.51 - $32.9 $165,500 - $190,984
-5,805 Reduced 26.18%
16,371 $529,000
Q4 2021

Feb 11, 2022

SELL
$26.37 - $34.22 $46,885 - $60,843
-1,778 Reduced 7.42%
22,176 $647,000
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $20,032 - $26,712
851 Added 3.68%
23,954 $639,000
Q1 2021

May 06, 2021

BUY
$24.15 - $31.45 $557,937 - $726,589
23,103 New
23,103 $605,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.95B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track First National Bank Of Omaha Portfolio

Follow First National Bank Of Omaha and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First National Bank Of Omaha, based on Form 13F filings with the SEC.

News

Stay updated on First National Bank Of Omaha with notifications on news.